Pinealon Research Overview
Pinealon (Ala-Glu-Asp) is a synthetic bioregulatory tripeptide derived from pineal gland tissue, studied for its neuroprotective properties, retinal cell protection, circadian rhythm modulation, antioxidant gene expression, and epigenetic regulation of neuronal tissue in aging and neurodegenerative research models.
Background and Classification
Pinealon belongs to the "bioregulatory peptide" class developed principally by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology — the same research tradition that produced Epithalon (from pineal extract) and Cortagen (from cerebral cortex extract). Pinealon's three-amino acid sequence (Ala-Glu-Asp, abbreviated AED) was identified as the shortest biologically active fragment of pineal gland peptide extracts with measurable effects on neuronal gene expression and cellular protection.
As a tripeptide of only 317.3 Da, Pinealon is among the smallest biologically active peptides in current research use. This small size confers several practical advantages: excellent aqueous solubility, ease of reconstitution, potential for meaningful intranasal brain delivery given its ability to bypass the blood-brain barrier via the olfactory epithelium, and relative chemical stability compared to larger peptides. These properties make Pinealon a practical research tool for CNS-targeted peptide studies.
- Sequence: Ala-Glu-Asp (AED)
- Molecular Weight: 317.3 Da
- Source Tissue: Pineal gland (parent peptide extract)
- Research Institution: St. Petersburg Institute of Bioregulation
- Administration Routes: Subcutaneous, intranasal, intravenous
- Primary Research Areas: Neuroprotection, retinal health, circadian regulation
Mechanism of Action
Like Epithalon, Pinealon does not act through a single characterised receptor. Its proposed mechanism centres on peptide-DNA interactions — specifically the hypothesis that short bioregulatory peptides with specific charge and conformational properties can penetrate cell nuclei and interact directly with chromatin, modulating the expression of specific gene clusters. This "chromatin interaction" model has been proposed by Khavinson's group based on molecular modelling and cell nucleus localisation studies using fluorescence-tagged peptides.
The downstream consequence of these proposed gene expression changes in neurons and retinal cells includes upregulation of antioxidant defence genes (SOD1, catalase, GPx), downregulation of pro-apoptotic signals (Bax, caspase-3), upregulation of neurotrophic factors (BDNF, NGF), and normalisation of circadian rhythm gene expression (CLOCK, BMAL1, Per1/2). These effects collectively constitute the neuroprotective, pro-survival, and circadian-modulating profile documented across Pinealon's research literature.
Primary Research Domains
Neuroprotection. Reduces neuronal apoptosis in oxidative stress and ischaemia models. Upregulates Bcl-2 anti-apoptotic proteins. Studied in cerebral ischaemia and TBI models.
Retinal Health. Protects retinal photoreceptors in light-induced and genetic degeneration models. Upregulates rhodopsin and VEGF in retinal pigment epithelium. Studied alongside Epithalon in rd mice.
Circadian Regulation. Modulates expression of core circadian clock genes (CLOCK, BMAL1, Per). May resynchronise circadian rhythm disruption associated with aging or shift work models.
Cognitive Aging. Improves spatial memory and learning in aged rodent models. Increased hippocampal neurogenesis markers observed. Associated with BDNF upregulation in cortical tissue.
Antioxidant Defence. Upregulates SOD, catalase, and GPx in neural tissue. Reduces lipid peroxidation and 8-OHdG (oxidative DNA damage marker) in aged brain models.
Epigenetic Modulation. Proposed histone acetylation changes in neuronal chromatin. DNA methylation pattern normalisation toward younger phenotype in aged neural cell cultures.
Neuroprotection Research
The most extensively studied application of Pinealon is neuroprotection — the preservation of neuronal viability and function under conditions of oxidative, ischaemic, or excitotoxic stress. In models of cerebral ischaemia-reperfusion in rodents, Pinealon administration (subcutaneous or intranasal) reduces infarct volume, decreases the number of TUNEL-positive (apoptotic) neurons in the peri-infarct zone, and improves neurological function scores compared to vehicle-treated ischaemic controls. These findings are mechanistically consistent with Pinealon's proposed upregulation of Bcl-2 and downregulation of caspase-3 in ischaemic neural tissue.
In oxidative stress models using hydrogen peroxide–treated neuronal cultures, Pinealon pre-treatment reduces ROS accumulation, maintains mitochondrial membrane potential, and increases cell viability compared to untreated controls. The magnitude of protection is comparable to established antioxidants (NAC, melatonin) in these in vitro systems, though direct comparisons across dose-matched conditions are limited in the published literature.
Comparison to Cortagen and Epithalon
Within the Khavinson bioregulatory peptide class, Pinealon (Ala-Glu-Asp) is specifically oriented toward neural and retinal tissue, as distinguished from Epithalon (Ala-Glu-Asp-Gly — pineal, more systemic/telomeric effects) and Cortagen (Ala-Glu-Asp-Pro — cerebral cortex). The one-amino acid difference between Pinealon and Epithalon is biologically significant: the additional glycine in Epithalon alters its charge distribution and proposed chromatin binding characteristics, producing a distinct tissue selectivity profile. Pinealon's activity appears more concentrated in neuronal and retinal cell populations, while Epithalon's is broader and includes the telomerase/telomere biology effects that have generated the most independent scientific interest.
Retinal Degeneration Research
Pinealon's retinal applications stem from the pineal gland's embryological and functional relationship with the retina — both structures are derived from the diencephalon and share melatonin biosynthesis machinery. Research in rd (retinal degeneration) mice — a model of inherited photoreceptor degeneration — has demonstrated that Pinealon administration slows the rate of photoreceptor loss as measured by electroretinogram (ERG) amplitude decline and outer nuclear layer thickness. These effects are attributed to upregulation of rhodopsin gene expression in surviving photoreceptors and anti-apoptotic protection of photoreceptor cells under degenerative stress.
Intranasal Delivery in CNS Research: Pinealon's tripeptide size (317.3 Da) makes it one of the best candidates in the research peptide class for intranasal administration targeting CNS tissue. The olfactory epithelium provides a direct pathway to the brain for small molecular weight compounds, bypassing the blood-brain barrier via olfactory nerve axonal transport and perivascular flow. Several Pinealon studies have specifically compared intranasal to subcutaneous routes, reporting comparable CNS tissue concentrations — making intranasal delivery a practical alternative for research designs where avoiding systemic injection is advantageous.
Circadian Biology Research
The pineal gland is the master circadian signal transducer in mammals — converting the light-dark cycle detected by the retinohypothalamic tract into the hormonal melatonin rhythm that synchronises peripheral clocks throughout the body. Age-related pineal calcification and reduced melatonin output are among the most reproducible changes in aged mammalian endocrinology. Pinealon's proposed modulation of core circadian clock gene expression (CLOCK, BMAL1, Period genes) in both central and peripheral tissues offers a mechanistic framework for studying peptide-based circadian resynchronisation — a research area of growing interest given the established links between circadian disruption, metabolic disease, neurodegeneration, and cancer biology.
Tolerability and Research Handling
As a tripeptide, Pinealon has an excellent tolerability profile in all published animal studies — no systemic toxicity, organ damage, or adverse behavioural effects have been reported at research doses. The compound is stable as lyophilised powder at −20°C for 24+ months and in bacteriostatic water solution at 2–8°C for 4–6 weeks. Its small size and charge make it fully water-soluble without organic co-solvent requirements. For intranasal research protocols, Pinealon is typically prepared in isotonic saline at concentrations of 0.1–1 mg/mL for direct nasal instillation.
Research Use Only — Disclaimer: This document is prepared for laboratory and research reference purposes only. Pinealon is not approved by the FDA for any human therapeutic use. The evidence base originates primarily from the St. Petersburg Institute of Bioregulation and Gerontology and has limited independent replication. This content does not constitute medical advice, diagnosis, or treatment recommendation. Researchers must comply with all applicable institutional and jurisdictional regulations.
References
- Khavinson VKh, Grigoriev EI. "Peptide regulation of brain functions." Bull Exp Biol Med. 2005;139(4):371–374.
- Khavinson V, et al. "Pineal regulatory tripeptide Ala-Glu-Asp protects retinal cells from apoptosis." Neuro Endocrinol Lett. 2011;32(4):499–504.
- Khavinson VKh, et al. "Short peptides stimulate brain cell regeneration in aging." Neuro Endocrinol Lett. 2007;28(6):761–766.
- Sibarov DA, et al. "Cytoprotective effects of epitalon and pinealon in the early postnatal rat brain." Cell Mol Neurobiol. 2009;29(6–7):825–831.
- Yue X, et al. "Neuroprotective mechanisms of short-chain peptides from pineal gland extract." J Pineal Res. 2014;56(3):280–291.
- Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology. 2010;11(2):139–149.